One PBM Clawed Back $100M From Iowa Medicaid Pharmacies

Iowa's Auditor of State⧉ spent years trying to answer a simple question: are the pharmacy benefit managers (PBMs) that process Iowa Medicaid's prescription claims quietly charging the state more than they pay pharmacies?▸ On June 10, 2026, Auditor Rob Sand released the answer his office could piece together despite the PBMs' resistance -- one of three PBMs whose reconciliations his office could analyze appears to have clawed back approximately $100 million from Iowa pharmacies over three years through a year-end accounting maneuver -- a mechanism the auditor's own report says does not always pass the resulting savings back to the Medicaid health plans billed for the higher amount. Sand calls it "a misuse of tax dollars." His office cannot say for certain how much it cost Iowa Medicaid overall, because the PBMs would not turn over the records that would prove it.

The mechanism is called an "effective rate."▸ A PBM initially reimburses a pharmacy for a prescription at one rate. Then, typically at year's end, it recalculates using a different, contractually guaranteed "effective rate" -- and if the pharmacy was paid more than that guarantee across the year, the PBM claws the difference back. The problem, according to Iowa's auditor, is what happens on the other side of the ledger: the managed care organization (MCO) that Iowa Medicaid pays to run the benefit continues paying the PBM based on the original, higher reimbursement figures, while the PBM quietly recovers money from pharmacies after the fact. The gap between what the MCO -- and by extension the state -- pays the PBM, and what the PBM ultimately pays pharmacies, is spread pricing, a practice Iowa Medicaid prohibits.

Iowa is not the first state to find PBMs profiting this way -- it is one of the latest in a chain that starts with Ohio.▸ Ohio's auditor exposed outright spread pricing in an August 2018 report⧉ that found PBMs administering its Medicaid managed-care pharmacy benefit had collected roughly $224.8 million in spread over a single year -- April 2017 through March 2018 -- including $208 million in fees on generic-drug claims alone, a markup averaging more than 31%. After Ohio banned that practice outright, Iowa's report says PBMs elsewhere shifted to subtler tactics that produced similar results through more convoluted paperwork -- including the kind of once-a-year, hard-to-trace reconciliation Iowa's auditor now says its own PBMs are using -- with comparable spread-pricing findings also surfacing in Kentucky, Georgia, Virginia, Maryland, and Florida, and, most recently, from Texas's own Medicaid inspector general.

The $100 million figure comes with an asterisk the report is explicit about: Sand's office says it cannot prove the practice's actual dollar harm to Iowa Medicaid, because it was denied access to the underlying financial records and systems it needed to complete the analysis, and because Medicaid and non-Medicaid pharmacy claims are comingled in ways that limited what the available data could show.▸ The PBMs asserted their pricing structures were trade secrets. The office did subpoena additional data and engaged an outside firm, 3Axis Advisors, to help analyze the claims-adjudication process -- but the report states plainly that "the inability or unwillingness of the PBMs to provide critical financial records and other information prevented a complete evaluation of compliance and financial practices."

The report does not even name the PBM behind the $100 million figure.▸ Sand's office reviewed claims tied to four PBMs serving Iowa Medicaid -- CVS, Evolve, Express Scripts, and IngenioRx -- but says it chose not to identify the one responsible for the finding because it "did not want to single out the single PBM that at least somewhat cooperated with our effort," and because naming it would also have opened the door for that PBM to sue the state over trade-secret claims. The state's own watchdog, in other words, found what it calls a misuse of tax dollars and then had to withhold the one detail -- who did it -- that would let anyone hold a specific company accountable.

Pennsylvania offers a third data point.▸ Its Auditor General found in August 2024⧉ that the state's Department of Human Services failed to adequately monitor $4.6 billion in Medicaid pharmacy spending in 2022, and that the resulting gap in oversight let PBM spread pricing cost Pennsylvania taxpayers $7 million that year alone. None of these three figures are directly comparable -- Iowa's covers one PBM over three years, Ohio's covers every PBM statewide in one year, Pennsylvania's covers one program's shortfall in a single year -- but together they are three independent state audits, three different administrations, finding the same basic pattern: PBMs paid to manage Medicaid drug costs are instead quietly capturing a share of them, and state oversight has consistently lagged behind the accounting techniques used to hide it.